Pinnacle Wealth Planning Services’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Pinnacle Wealth Planning Services's NBIX Position: Q3 2026 in Review
Pinnacle Wealth Planning Services increased its Neurocrine Biosciences (NBIX) stake by 3.8% in Q3 2026, buying an estimated $321 and bringing the position to 55 shares worth $7.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2176.
Pinnacle Wealth Planning Services first reported a position in NBIX in Q4 2020 and has held it in 5 quarters since. The position peaked at $8.93K in Q2 2026. 773 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- Pinnacle Wealth Planning Services held 55 shares of Neurocrine Biosciences worth $7.8K as of Q3 2026.
- Pinnacle Wealth Planning Services bought 2 Neurocrine Biosciences shares in Q3 2026, an estimated $321.
- Neurocrine Biosciences made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q3 2026, its #2176 holding.
- Pinnacle Wealth Planning Services first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 5 quarters since.
- Pinnacle Wealth Planning Services's Neurocrine Biosciences position peaked at $8.93K in Q2 2026.
- 773 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on Pinnacle Wealth Planning Services's 13F filing for Q3 2026, filed 27 Oct 2026.